GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in development for the treatment of Metastatic castration-resistant prostate cancer (mCRPC).¹ The agreement grants GSK the exclusive rights to the development and commercialization of the ADC worldwide.

Sasha Koniev, chief executive officer at Syndivia, touched on the agreement in a press release, saying, “We are proud that GSK will advance this program on a global scale. This agreement underscores the value of our GeminiMab ADC platform and the opportunity to bring a promising new therapy to patients with pressing unmet medical needs.”

Why did GSK want Syndivia’smCRPC ADC?

Syndivia developed its ADC using the next-generation GeminiMab conjugation technology, helping the ADC display enhanced anti-tumor activity while also displaying its safety profile and demonstrating best-in-class potential.¹ During testing in preclinical studies, the ADC showed effectiveness at shrinking tumors without causing a proportional increase in significant side effects, including higher dosage amounts. Additionally, the ADC showed potential to provide a targeted treatment directly to the tumor (currently a gap in available therapies) and offers patients an easily accessible treatment in the community practice setting for mCRPC.¹ The acquisition builds on GSK’s developing pipeline, which includes ADCs with distinct antigens and payloads, next-generation small molecules, and T-cell engagers.¹ GSK’s GSK’227 ADC ,and now Syndivia’s mCRPC focused ADC, enables GSK to advance its potential therapeutic options across various stages and types of prostate cancer.¹

What are the financial implications of the agreement?

As stated in the terms of the agreement, Syndivia is set to receive an upfront payment, success-based development payments, and commercial milestone payments. The total value of the sale is about $357 million.¹ Syndivia is also set to receive tiered royalties on future product sales worldwide. Terms of the agreement grant GSK full responsibility for the development, manufacturing, and worldwide commercialization of the ADC program.¹

Why is GSK focusing on Metastatic castration-resistant prostate cancer treatments?

An estimated 1.4 million men worldwide are diagnosed with prostate cancer each year, with upwards of 10-20% developing advanced disease (such as castration resistance with metastases) within five years of diagnoses.¹ According to a report from GSK, patients with cancer that has advanced to mCRPC have limited options for targeted treatment, along with difficult to access standard of care options in their respective community practice settings. Recorded survival rates for these patients are low, as patients typically are given a 5-year survival rate of approximately 30%, and a median survival of approximately two years.¹

Hesham Abdullah, senior vice president and global head of oncology and R&D at GSK, mentioned the company’s focus on mCRPC treatments, saying, “Prostate cancer represents a significant health burden and an emerging area of growth for GSK, where targeted therapies are urgently needed in metastatic castration-resistant settings. The addition of this ADC builds on GSK's growing portfolio and strengths in tumor-targeted technologies, including GSK’227, our B7-H3-targeting ADC.”

Sources

1. GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer GSK October 27, 2025 https://www.gsk.com/en-gb/media/press-releases/gsk-acquires-exclusive-rights-from-syndivia-for-antibody-drug-conjugate/ 
2. GSK targets Syndivia’s prostate cancer ADC in £268m buy Yahoo Finance October 27, 2025 https://finance.yahoo.com/news/gsk-targets-syndivia-prostate-cancer-162307875.html